cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.26936100
title: Association of ACEI/ARB therapy with total and cardiovascular death in coronary artery disease patients with advanced chronic kidney disease: a large multi-center longitudinal study

description: Advanced chronic kidney disease (CKD) is common among patients with coronary artery disease (CAD), and angiotensin‑converting enzyme inhibitors (ACEI) or angiotensin‑receptor blockers (ARB) can improve cardiac and renal function, but whether ACEI/ARB therapy improves long-term prognosis remains unclear among these high-risk patients. Therefore, this research aimed to investigate the relationship between ACEI/ARB therapy and long-term prognosis among CAD patients with advanced CKD. CAD patients with advanced CKD were included in five hospitals. Advanced CKD was defined as estimated glomerular filtration rate (eGFR)&lt;30 ml/min per 1.73 m<sup>2</sup>. Cox regression models and competing risk Fine and Gray models were used to examine the relationship between ACEI/ARB therapy and all-cause and cardiovascular death, respectively. Of 2527 patients, 47.6% population of our cohort was discharged on ACEI/ARB. The overall all-cause and cardiovascular mortality were 38.6% and 24.7%, respectively. Multivariate Cox regression analyses indicated that ACEI/ARB therapy was found to be associated with lower rates of both all-cause mortality (hazard ratio (HR)=0.836, 95% confidence interval (CI): 0.738–0.948, <i>p</i> = 0.005) and cardiovascular mortality (HR = 0.817, 95%CI: 0.699–0.956, <i>p</i> = 0.011). In the propensity-matched cohort, the survival benefit was consistent, and significantly better survival was observed for all-cause mortality (HR = 0.856, 95%CI: 0.752–0.974, <i>p</i> = 0.019) and cardiovascular mortality (HR = 0.830, 95%CI: 0.707–0.974, <i>p</i> = 0.023) among patients treated with ACEI/ARB. ACEI/ARB therapy showed a better survival benefit among high-risk CAD patients with advanced CKD at long-term follow-up, which manifested that strategies to maintain ACEI/ARB treatment may improve clinical outcomes among these high-risk populations. Advanced CKD is highly prevalent and strongly associated with higher mortality risk and worse outcomes among CAD patients, and patients with advanced CKD have often been excluded from randomized controlled trials, creating an evidence gap for these high-risk CAD patients. ACEI/ARB are beneficial for greater survival among CAD patients, but the effect of ACEI/ARB therapy on long-term prognosis is unclear among CAD patients with advanced CKD. ACEI/ARB treatment showed a better survival benefit among high-risk CAD patients with advanced CKD at long-term follow-up. CAD patients with advanced CKD are not only have worse outcomes but also limited in their choice of therapy strategies. Our study may prompt an important reference for the subsequent improvement of long-term prognosis among these high-risk populations.
DOI: 10.6084/m9.figshare.26936100.v1
title: Association of ACEI/ARB therapy with total and cardiovascular death in coronary artery disease patients with advanced chronic kidney disease: a large multi-center longitudinal study

description: Advanced chronic kidney disease (CKD) is common among patients with coronary artery disease (CAD), and angiotensin‑converting enzyme inhibitors (ACEI) or angiotensin‑receptor blockers (ARB) can improve cardiac and renal function, but whether ACEI/ARB therapy improves long-term prognosis remains unclear among these high-risk patients. Therefore, this research aimed to investigate the relationship between ACEI/ARB therapy and long-term prognosis among CAD patients with advanced CKD. CAD patients with advanced CKD were included in five hospitals. Advanced CKD was defined as estimated glomerular filtration rate (eGFR)&lt;30 ml/min per 1.73 m<sup>2</sup>. Cox regression models and competing risk Fine and Gray models were used to examine the relationship between ACEI/ARB therapy and all-cause and cardiovascular death, respectively. Of 2527 patients, 47.6% population of our cohort was discharged on ACEI/ARB. The overall all-cause and cardiovascular mortality were 38.6% and 24.7%, respectively. Multivariate Cox regression analyses indicated that ACEI/ARB therapy was found to be associated with lower rates of both all-cause mortality (hazard ratio (HR)=0.836, 95% confidence interval (CI): 0.738–0.948, <i>p</i> = 0.005) and cardiovascular mortality (HR = 0.817, 95%CI: 0.699–0.956, <i>p</i> = 0.011). In the propensity-matched cohort, the survival benefit was consistent, and significantly better survival was observed for all-cause mortality (HR = 0.856, 95%CI: 0.752–0.974, <i>p</i> = 0.019) and cardiovascular mortality (HR = 0.830, 95%CI: 0.707–0.974, <i>p</i> = 0.023) among patients treated with ACEI/ARB. ACEI/ARB therapy showed a better survival benefit among high-risk CAD patients with advanced CKD at long-term follow-up, which manifested that strategies to maintain ACEI/ARB treatment may improve clinical outcomes among these high-risk populations. Advanced CKD is highly prevalent and strongly associated with higher mortality risk and worse outcomes among CAD patients, and patients with advanced CKD have often been excluded from randomized controlled trials, creating an evidence gap for these high-risk CAD patients. ACEI/ARB are beneficial for greater survival among CAD patients, but the effect of ACEI/ARB therapy on long-term prognosis is unclear among CAD patients with advanced CKD. ACEI/ARB treatment showed a better survival benefit among high-risk CAD patients with advanced CKD at long-term follow-up. CAD patients with advanced CKD are not only have worse outcomes but also limited in their choice of therapy strategies. Our study may prompt an important reference for the subsequent improvement of long-term prognosis among these high-risk populations.
DOI: 10.5281/zenodo.18331464
title: Stage23 Reconstruction Closure (AQCAL, FULL12) — FULL Evidence Pack (LOCKED)

description: This record provides a locked, downloader-ready FULL evidence pack for the Stage23 reconstruction → prediction → closure workflow (AQCAL, FULL12). The deposit includes the complete Stage23 FULL12 AQCAL run directory (per-configuration Stage2 predictions and Stage3 closure outputs) and the corresponding locked closure summary directories with MANIFEST/SHA256 checks.

Downloader integrity check:





tar -xzf STAGE23_FULL_EVIDENCE_V2b_20260121_224152.tar.gz




cd STAGE23_FULL_EVIDENCE_V2_*/




sha256sum -c PACK_SHA256SUMS.txt
DOI: 10.5281/zenodo.18331465
title: Stage23 Reconstruction Closure (AQCAL, FULL12) — FULL Evidence Pack (LOCKED)

description: This record provides a locked, downloader-ready FULL evidence pack for the Stage23 reconstruction → prediction → closure workflow (AQCAL, FULL12). The deposit includes the complete Stage23 FULL12 AQCAL run directory (per-configuration Stage2 predictions and Stage3 closure outputs) and the corresponding locked closure summary directories with MANIFEST/SHA256 checks.

Downloader integrity check:





tar -xzf STAGE23_FULL_EVIDENCE_V2b_20260121_224152.tar.gz




cd STAGE23_FULL_EVIDENCE_V2_*/




sha256sum -c PACK_SHA256SUMS.txt
DOI: 10.6084/m9.figshare.27283234
title: Effectiveness and safety of B cell-targeting biologics in the treatment of lupus nephritis: a systematic review and network meta‑analysis

description: To evaluate the effectiveness and safety of different B cell-targeting biological agents combining with standard of care in patients with lupus nephritis (LN). Comprehensive literature searches were conducted using PubMed, Embase, Web of Science, and Central in the Cochran Library, spanning from inception to May 20th, 2024. Randomized control trials (RCTs) comparing rituximab (RTX), belimumab, ocrelizumab, obinutuzumab, and anifrolumab in LN were selected. The primary outcomes of interest were related to complete renal remission (CRR), and partial renal remission (PRR). Additionally, we delved into safety outcomes, examining the occurrence of serious adverse events (SAEs), infections, and the discontinuation rates due to adverse events. A total of 6 RCTs with 1150 patients applying various B cell-targeting biological agents were included. Notably, ranking probability based on the surface under the cumulative ranking curve (SUCRA) indicated that obinutuzumab (SUCRA 85.2%) has the highest potential superiority in improving CRR, followed by belimumab, ocrelizumab. Regarding the improvement in PRR, obinutuzumab (SUCRA 83.0%) has the highest potential superiority. In terms of safety, with a focus on SAEs, infections, and the discontinuation rates due to adverse events, the results were: SUCRA-based ranking indicated that RTX (SUCRA 74.1%) had the highest probability of postponing SAEs, followed by belimumab and obinutuzumab. Concerning infection reduction, anifrolumab (SUCRA 78.7%) had the highest potential superiority. Safety events monitoring infection occurred better with RTX than with standard therapy (OR = 3.57, 95% CI 1.02, 12.66) and were statistically different. For the discontinuation rates due to adverse events, RTX (SUCRA 88.6%) demonstrated the highest potential superiority. Concerning the effectiveness and safety outcomes, obinutuzumab, belimumab, and RTX plus standard of care may be superior to the current standard therapy as treatments for LN. This study protocol has been registered with PROSPERO, with a registration number of CRD42024548522.
DOI: 10.6084/m9.figshare.27283234.v1
title: Effectiveness and safety of B cell-targeting biologics in the treatment of lupus nephritis: a systematic review and network meta‑analysis

description: To evaluate the effectiveness and safety of different B cell-targeting biological agents combining with standard of care in patients with lupus nephritis (LN). Comprehensive literature searches were conducted using PubMed, Embase, Web of Science, and Central in the Cochran Library, spanning from inception to May 20th, 2024. Randomized control trials (RCTs) comparing rituximab (RTX), belimumab, ocrelizumab, obinutuzumab, and anifrolumab in LN were selected. The primary outcomes of interest were related to complete renal remission (CRR), and partial renal remission (PRR). Additionally, we delved into safety outcomes, examining the occurrence of serious adverse events (SAEs), infections, and the discontinuation rates due to adverse events. A total of 6 RCTs with 1150 patients applying various B cell-targeting biological agents were included. Notably, ranking probability based on the surface under the cumulative ranking curve (SUCRA) indicated that obinutuzumab (SUCRA 85.2%) has the highest potential superiority in improving CRR, followed by belimumab, ocrelizumab. Regarding the improvement in PRR, obinutuzumab (SUCRA 83.0%) has the highest potential superiority. In terms of safety, with a focus on SAEs, infections, and the discontinuation rates due to adverse events, the results were: SUCRA-based ranking indicated that RTX (SUCRA 74.1%) had the highest probability of postponing SAEs, followed by belimumab and obinutuzumab. Concerning infection reduction, anifrolumab (SUCRA 78.7%) had the highest potential superiority. Safety events monitoring infection occurred better with RTX than with standard therapy (OR = 3.57, 95% CI 1.02, 12.66) and were statistically different. For the discontinuation rates due to adverse events, RTX (SUCRA 88.6%) demonstrated the highest potential superiority. Concerning the effectiveness and safety outcomes, obinutuzumab, belimumab, and RTX plus standard of care may be superior to the current standard therapy as treatments for LN. This study protocol has been registered with PROSPERO, with a registration number of CRD42024548522.
DOI: 10.6084/m9.figshare.27887088
title: Innovative management of peritoneal catheter malfunction caused by omental wrapping: exploration the modified low-temperature plasma ablation blade <i>in vivo</i> and <i>in vitro</i>

description: Omental wrapping is a common complication of peritoneal dialysis, which manifests as catheter malfunction causing early termination of peritoneal dialysis. This study investigates the efficacy and safety of a Modified Low-Temperature Plasma Ablation (MLTPA) blade in treating omental-wrapped catheter malfunction. <i>In vitro</i> experiments using the MLTPA blade at the 5th power level were conducted to ablate omental tissues and catheters, evaluating ablation effects and potential catheter damage. <i>In vivo</i>, nine beagles were modeled for catheter malfunction due to omental wrapping, randomized into MLTPA blade (<i>n</i> = 5) and the Gastroscopic Biopsy Forceps (GBF) groups (<i>n</i> = 4). Dialysate outflow velocity, dialysate residual volume, and complications were recorded. <i>In vitro</i> experiments showed that the MLTPA blade effectively ablated omental tissue without damaging the catheter at the 5th power level. <i>In vivo</i>, the MLTPA blade group achieved a 100% (5/5) catheter recanalization success rate, significantly increasing catheter outflow velocity (111.4 ± 5.1 ml vs. 3.0 ± 1.0 ml, <i>p</i> &lt; 0.0001), and reducing dialysate residual volume after ablation (81.0 ± 5.6 ml vs. 976.8 ± 4.6 ml, <i>p</i> &lt; 0.0001). Treatment failures in the GBF group (4/4) were successfully resolved with MLTPA treatment. No significant differences in outflow velocity of dialysate were observed at 3 and 7 days post-canalization in the MLTPA blade group, without severe bleeding, infection, catheter migration, or organ damage. The MLTPA blade rapidly ablates omentum within the lumen, recovering catheter function without severe complications. These findings provide preliminary evidence supporting the safety and feasibility of using the MLTPA blade to treat catheter malfunction caused by omental wrapping.
DOI: 10.6084/m9.figshare.27887088.v1
title: Innovative management of peritoneal catheter malfunction caused by omental wrapping: exploration the modified low-temperature plasma ablation blade <i>in vivo</i> and <i>in vitro</i>

description: Omental wrapping is a common complication of peritoneal dialysis, which manifests as catheter malfunction causing early termination of peritoneal dialysis. This study investigates the efficacy and safety of a Modified Low-Temperature Plasma Ablation (MLTPA) blade in treating omental-wrapped catheter malfunction. <i>In vitro</i> experiments using the MLTPA blade at the 5th power level were conducted to ablate omental tissues and catheters, evaluating ablation effects and potential catheter damage. <i>In vivo</i>, nine beagles were modeled for catheter malfunction due to omental wrapping, randomized into MLTPA blade (<i>n</i> = 5) and the Gastroscopic Biopsy Forceps (GBF) groups (<i>n</i> = 4). Dialysate outflow velocity, dialysate residual volume, and complications were recorded. <i>In vitro</i> experiments showed that the MLTPA blade effectively ablated omental tissue without damaging the catheter at the 5th power level. <i>In vivo</i>, the MLTPA blade group achieved a 100% (5/5) catheter recanalization success rate, significantly increasing catheter outflow velocity (111.4 ± 5.1 ml vs. 3.0 ± 1.0 ml, <i>p</i> &lt; 0.0001), and reducing dialysate residual volume after ablation (81.0 ± 5.6 ml vs. 976.8 ± 4.6 ml, <i>p</i> &lt; 0.0001). Treatment failures in the GBF group (4/4) were successfully resolved with MLTPA treatment. No significant differences in outflow velocity of dialysate were observed at 3 and 7 days post-canalization in the MLTPA blade group, without severe bleeding, infection, catheter migration, or organ damage. The MLTPA blade rapidly ablates omentum within the lumen, recovering catheter function without severe complications. These findings provide preliminary evidence supporting the safety and feasibility of using the MLTPA blade to treat catheter malfunction caused by omental wrapping.
DOI: 10.6084/m9.figshare.27900835
title: Risk factors for venous thromboembolism in patients with chronic kidney disease: a systematic review and meta-analysis

description: The objective of this study was to conduct a meta-analysis and systematic review to identify the risk factors contributing to thromboembolism (VTE) in chronic kidney disease (CKD) patients. PubMed, Cochrane Library, Web of Science, and Embase databases were searched from inception to October 2024. Cohort, case-control, and cross-sectional studies examining risk factors for VTE in CKD were included. Quality assessment and data extraction were conducted. Fourteen studies were analyzed. CKD stage 2 (OR: 1.15, 95% CI: 1.06–1.25, <i>p</i> &lt; .01), CKD stage 3 (OR: 2.28, 95% CI: 1.76–2.95, <i>p</i> &lt; .01), CKD stage 3–4 (OR: 1.57, 95% CI: 1.17–2.1, <i>p</i> &lt; .01), end-stage renal disease (OR: 3.68, 95% CI: 1.02–13.27, <i>p</i> &lt; .01), female (OR: 1.30, 95% CI: 1.15–1.48, <i>p</i> &lt; .01), congestive heart failure (CHF) (OR: 1.26, 95% CI: 1.09–1.46, <i>p</i> &lt; .01), atrial fibrillation (AF) (OR: 1.97, 95% CI: 1.40–2.97, <i>p</i> &lt; .01), coronary artery disease (CAD) (OR: 1.28, 95% CI: 1.05–1.56, <i>p</i> = .01), and systemic lupus erythematosus (SLE) (OR: 3.06, 95% CI: 1.57–5.94, <i>p</i> &lt; .01) were associated with increased risk of VTE. In addition, in sensitivity analyses, hemodialysis increased the risk of VTE compared with peritoneal dialysis (OR: 2.35, 95% CI: 1.34–4.14, <i>p</i> &lt; .01). Different CKD stages, female, CHF, AF, CAD, and SLE emerge as significant risk factors for VTE in CKD patients. Additionally, VTE risk can be influenced by dialysis modality and other factors. Physicians should comprehensively assess the risk of VTE in patients with CKD.
DOI: 10.6084/m9.figshare.27900835.v1
title: Risk factors for venous thromboembolism in patients with chronic kidney disease: a systematic review and meta-analysis

description: The objective of this study was to conduct a meta-analysis and systematic review to identify the risk factors contributing to thromboembolism (VTE) in chronic kidney disease (CKD) patients. PubMed, Cochrane Library, Web of Science, and Embase databases were searched from inception to October 2024. Cohort, case-control, and cross-sectional studies examining risk factors for VTE in CKD were included. Quality assessment and data extraction were conducted. Fourteen studies were analyzed. CKD stage 2 (OR: 1.15, 95% CI: 1.06–1.25, <i>p</i> &lt; .01), CKD stage 3 (OR: 2.28, 95% CI: 1.76–2.95, <i>p</i> &lt; .01), CKD stage 3–4 (OR: 1.57, 95% CI: 1.17–2.1, <i>p</i> &lt; .01), end-stage renal disease (OR: 3.68, 95% CI: 1.02–13.27, <i>p</i> &lt; .01), female (OR: 1.30, 95% CI: 1.15–1.48, <i>p</i> &lt; .01), congestive heart failure (CHF) (OR: 1.26, 95% CI: 1.09–1.46, <i>p</i> &lt; .01), atrial fibrillation (AF) (OR: 1.97, 95% CI: 1.40–2.97, <i>p</i> &lt; .01), coronary artery disease (CAD) (OR: 1.28, 95% CI: 1.05–1.56, <i>p</i> = .01), and systemic lupus erythematosus (SLE) (OR: 3.06, 95% CI: 1.57–5.94, <i>p</i> &lt; .01) were associated with increased risk of VTE. In addition, in sensitivity analyses, hemodialysis increased the risk of VTE compared with peritoneal dialysis (OR: 2.35, 95% CI: 1.34–4.14, <i>p</i> &lt; .01). Different CKD stages, female, CHF, AF, CAD, and SLE emerge as significant risk factors for VTE in CKD patients. Additionally, VTE risk can be influenced by dialysis modality and other factors. Physicians should comprehensively assess the risk of VTE in patients with CKD.
DOI: 10.6084/m9.figshare.26311726.v1
title: Mesangial cell-derived CircRNAs in chronic glomerulonephritis: RNA sequencing and bioinformatics analysis

description: Circular RNAs (circRNAs) have been shown to play critical roles in the initiation and progression of chronic glomerulonephritis (CGN), while their role from mesangial cells in contributing to the pathogenesis of CGN is rarely understood. Our study aims to explore the potential functions of mesangial cell-derived circRNAs using RNA sequencing (RNA-seq) and bioinformatics analysis. Mouse mesangial cells (MMCs) were stimulated by lipopolysaccharide (LPS) to establish an <i>in vitro</i> model of CGN. Pro-inflammatory cytokines and cell cycle stages were detected by Enzyme-linked immunosorbent assay (ELISA) and Flow Cytometry experiment, respectively. Subsequently, differentially expressed circRNAs (DE-circRNAs) were identified by RNA-seq. GEO microarrays were used to identify differentially expressed mRNAs (DE-mRNAs) between CGN and healthy populations. Weighted co-expression network analysis (WGCNA) was utilized to explore clinically significant modules of CGN. CircRNA-associated CeRNA networks were constructed by bioinformatics analysis. The hub mRNAs from CeRNA network were identified using LASSO algorithms. Furthermore, utilizing protein–protein interaction (PPI), gene ontology (GO), pathway enrichment (KEGG), and GSEA analyses to explore the potential biological function of target genes from CeRNA network. In addition, we investigated the relationships between immune cells and hub mRNAs from CeRNA network using CIBERSORT. The expression of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α was drastically increased in LPS-induced MMCs. The number of cells decreased significantly in the G1 phase but increased significantly in the S/G2 phase. A total of 6 DE-mRNAs were determined by RNA-seq, including 4 up-regulated circRNAs and 2 down-regulated circRNAs. WGCNA analysis identified 1747 DE-mRNAs of the turquoise module from CGN people in the GEO database. Then, the CeRNA networks, including 6 circRNAs, 38 miRNAs, and 80 mRNAs, were successfully constructed. The results of GO and KEGG analyses revealed that the target mRNAs were mainly enriched in immune, infection, and inflammation-related pathways. Furthermore, three hub mRNAs (BOC, MLST8, and HMGCS2) from the CeRNA network were screened using LASSO algorithms. GSEA analysis revealed that hub mRNAs were implicated in a great deal of immune system responses and inflammatory pathways, including IL-5 production, MAPK signaling pathway, and JAK-STAT signaling pathway. Moreover, according to an evaluation of immune infiltration, hub mRNAs have statistical correlations with neutrophils, plasma cells, monocytes, and follicular helper T cells. Our findings provide fundamental and novel insights for further investigations into the role of mesangial cell-derived circRNAs in CGN pathogenesis.